List view / Grid view
22 February 2017 | By Professor Josep Tabernero, Chair of the ESMO Cancer Medicines Working Group
Dr Josep Tabernero explains the benefits of biosimilars, showing how they can create sustainable, safe and affordable access to medicine globally...
8 December 2016 | By Dolomite Bio
Researchers at The Institute of Cancer Research (ICR), London, are taking advantage of the single cell encapsulation capabilities of Dolomite Bio’s Single Cell RNA-Seq System to investigate resistance mechanisms in prostate cancer...
10 October 2016 | By Niamh Louise Marriott, Digital Content Producer
The new data-driven tech, OncoPortal, improves the diagnosis and treatment of solid tumours and haematological malignancies for patients around the world...
5 September 2016 | By Niamh Louise Marriott, Digital Content Producer
RM radiation doses were significantly higher in the patients who did not receive predosing, indicating that pre-dosing with lilotomab has a protective...
8 August 2016 | By New England Biolabs, Inc.
Novel target enrichment technology, compatible with low input amounts from challenging sample types, uses a one-day workflow...
21 July 2016 | By Niamh Louise Marriott, Digital Content Producer
global pharmaceutical company GlaxoSmithKline has been established to discover and develop novel medicines to treat aggressive forms of blood cancer...
20 July 2016 | By Niamh Louise Marriott, Digital Content Producer
With the EU orhpan drug designations, Cell Medica can now obtain regulatory and financial incentives for developing and marketing CMD-003 as a cancer...
19 July 2016 | By Niamh Louise Marriott
Gazyvaro did not meet its primary endpoint of significantly reducing the risk of disease worsening or death in people with diffuse large B-cell lymphoma...
In this issue: Regulation, Oncology, Single Use, Robotics, Microbiology, PAT, Mass Spectrometry, Drug Delivery, Nanotechnology, and much more...
29 May 2015 | By VIctoria White
Janssen and Bayer have launched a clinical research programme evaluating rivaroxaban for the prevention and treatment of blood clots in patients with cancer...
15 December 2013 | By Klarke M. Sample and Roy Bicknell, University of Birmingham
It is possible to attack the vasculature within solid tumours and achieve an anti-cancer effect. In the last decade, a number of studies have utilised cDNA libraries, SAGE analysis and microarrays to identify potential drug targets in the tumour endothelium. Modern sequencing technologies are likely to be a far more…
9 July 2012 | By European Medicines Agency (EMA)
The EMA has been notified by Sanofi-aventis of its decision to withdraw its marketing authorisation application for Mulsevo...
